← Leaderboards
Tristan Maerz
University Of Michigan At Ann Arbor
$2,131,366
Attributed
$2,700,349
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $976.6K · FY2021–24$1M$750K$500K$250K$0
'21
'22
'23
'24
Funding mix
By agency
NIH$2,700,349 · 4
By mechanism
R01$1,562,383 · 1
R21$1,137,966 · 3
Top collaborators
- Rhima Coleman2 shared
- Omolola Eniola-Adefeso2 shared
- Andrea I Alford1 shared
Most similar at University Of Michigan At Ann Arbor
Same institution · by research overlap
- Andrea I Alford$780,297
- Christiane Wobus$7,155,858
- Mohammed Akaaboune$6,423,588
- Greg Thurber$4,032,895
- James R Baker$11,149,531
Others in their field
Other Emerging Leaders on “Chondrocytes”
- Jie Shen · Washington University$6,941,612
- Maddalena Adorno · Dorian Therapeutics, Inc.$4,178,124
- April Marie Craft · Boston Children'S Hospital$4,067,178
- Terence D Capellini · Massachusetts General Hospital$3,762,687
- Tendy Chiang · Research Inst Nationwide Children'S Hosp$3,672,010
- Tao Yang · Van Andel Research Institute$3,424,841
Research focus
ChondrocytesJointsCellsPeptide HydrolasesCell TypeArthropathiesInflammatoryInjuryResponseTissuesSynovitisJoint InjuryCartilageMacrophageIn VivoInjectionsIn VitroEffective TherapyPathologicDoctor Of PhilosophyMatrix MetalloproteinasesPathway InteractionsJoint DestructionBiomedical Engineering
Grant awards (8)
Sustained Biomaterial-mediated Inhibition of R-spondin 2 to Target Pathological Wnt Signaling in Post-Traumatic Osteoarthritis$506,598
R01 · FY2024 · AR · contact PI
Autonomous RUNX2 suppression in genetically modified stem cell-derived chondrocytes as a disease modifying therapeutic for PTOA$157,946
R21 · FY2024 · AR
Sustained Biomaterial-mediated Inhibition of R-spondin 2 to Target Pathological Wnt Signaling in Post-Traumatic Osteoarthritis$520,668
R01 · FY2023 · AR · contact PI
Bioerodible corticosteroid microparticle-drug as an intra-articular drug delivery system for osteoarthritis therapy$258,334
R21 · FY2023 · AR · contact PI
Autonomous RUNX2 suppression in genetically modified stem cell-derived chondrocytes as a disease modifying therapeutic for PTOA$197,567
R21 · FY2023 · AR
Sustained Biomaterial-mediated Inhibition of R-spondin 2 to Target Pathological Wnt Signaling in Post-Traumatic Osteoarthritis$535,117
R01 · FY2022 · AR · contact PI
Bioerodible corticosteroid microparticle-drug as an intra-articular drug delivery system for osteoarthritis therapy$146,599
R21 · FY2022 · AR
Targeting Pathological Angiogenesis after Joint Injury$377,520
R21 · FY2021 · AR · contact PI